top of page
  • MindMate Staff

The newest developments in dementia research

Clinical research is crucial to find new treatments, diagnostics, and cures for chronic diseases worldwide. Especially research for different types of dementia diseases such as Alzheimer’s disease or MCI has made impressive progress over the past years. Today, we will take a look into the newest developments in dementia research and what that means for people living with these conditions.

A research study of Lewy body dementia supports ties to Alzheimer's and Parkinson's diseases

Researchers from the National Institute of Neurological Disorders and Stroke have found that five genes may play an essential role in determining whether a person might suffer from Lewy body dementia. This disorder is especially devastating as it riddles the brain with clumps of abnormal protein deposits called Lewy bodies. The results of the clinical study also support the disorder’s ties to Parkinson’s and Alzheimer’s disease.

A new study provides insights into the architecture of abnormal protein deposits in brain disorders

Scientists from the Case Western Reserve University have determined the structure of a protein called ‘fibrils’ linked to Lou Gehrig’s disease and other neurodegenerative disorders. The findings point out the toxicity of protein clumping and the spread between nerve cells in the brain.

Two new genes linked to Alzheimer’s disease

The research team around Chunshui Yu and Mulin Jun Li of the Tianjin Medical University has discovered two new genes that are potentially involved in Alzheimer’s disease. The genes were discovered while researchers were looking into which genes would turn on and off in the hippocampus, a complex brain structure embedded deep into the temporal lobe. It has a major role in the learning and memory, of people living with the disease.

New discovery of biomarker could help predict Alzheimer's years before symptoms emerge

Researchers of the Edith Cowan University have found a unique brain protein measured in the blood of patients that could be used to diagnose Alzheimer’s disease decades before first symptoms are developing. The study is the first one suggesting that people with elevated glial fibrillary acidic Protein (GFAP) in the blood may also have increased amyloid-beta in their brain, which is associated with Alzheimer’s disease.

Join Mindmate to increase your brain functionality

Do you want to learn more about Alzheimer’s disease and try out different methods to stimulate your brain function? Sign up for our Mindmate app and enjoy brain games to improve your memory, exercises, and lifestyle hacks that can benefit your cognitive function.

Sign up here.


bottom of page